Last reviewed 2026-05-26 · How we verify

Camyna (TIOXOLONE)

Phase 2 active Small molecule ✓ Verified May 2026

Camyna (generic name: TIOXOLONE) is a tioxolone drug. It is currently in Phase 2 development.

Camyna works by inhibiting the enzyme carbonic anhydrase 2, which helps regulate the balance of acid and base in the body.

Camyna is a small molecule with the synonyms TIOXOLONA, TIOXOLONE, and TIOXOLONE.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	TIOXOLONE
Drug class	tioxolone
Target	Amine oxidase [flavin-containing] A, Amine oxidase [flavin-containing] B, Carbonic anhydrase 2
Modality	Small molecule
Therapeutic area	Pain
Phase	Phase 2

Mechanism of action

Think of it like a leaky faucet - carbonic anhydrase 2 helps control how much acid flows into the body's cells. When Camyna blocks this enzyme, it can help reduce the amount of acid that builds up, which can be beneficial for people with certain conditions. This can help alleviate symptoms such as pain and swelling.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Camyna CI brief — competitive landscape report
Camyna updates RSS · CI watch RSS

Frequently asked questions about Camyna

What is Camyna?

Camyna (TIOXOLONE) is a tioxolone drug.

How does Camyna work?

Camyna works by inhibiting the enzyme carbonic anhydrase 2, which helps regulate the balance of acid and base in the body.

What is the generic name of Camyna?

TIOXOLONE is the generic (nonproprietary) name of Camyna.

What drug class is Camyna in?

Camyna belongs to the tioxolone class. See all tioxolone drugs at /class/tioxolone.

What development phase is Camyna in?

Camyna is in Phase 2.

What does Camyna target?

Camyna targets Amine oxidase [flavin-containing] A, Amine oxidase [flavin-containing] B, Carbonic anhydrase 2 and is a tioxolone.

Drug class: All tioxolone drugs
Target: All drugs targeting Amine oxidase [flavin-containing] A, Amine oxidase [flavin-containing] B, Carbonic anhydrase 2
Therapeutic area: All drugs in Pain

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing